Ultragenyx Pharmaceutical Q2 2026 Earnings Report

Ultragenyx Pharmaceutical EPS Results

• Actual EPS: N/A
• Consensus EPS: -$1.21
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Ultragenyx Pharmaceutical Revenue Results

• Actual Revenue: N/A
• Expected Revenue: $183.08 million
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Ultragenyx Pharmaceutical Announcement Details

• Quarter: Q2 2026
• Date: 8/4/2026
• Time: After Market Closes
• Conference Call Date: Tuesday, August 4, 2026
• Conference Call Time: 5:00PM ET

Ultragenyx Pharmaceutical (NASDAQ:RARE) is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.

The company’s commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders. These products illustrate Ultragenyx’s approach of targeting well-defined genetic defects with therapies designed to correct or mitigate the underlying cause of disease. Ultragenyx maintains a robust clinical pipeline, with investigational treatments in various stages of development for conditions such as congenital hyperinsulinism, pyruvate kinase deficiency and other rare enzymatic or metabolic disorders.

Ultragenyx operates globally, with a commercial presence in the United States, Europe and Canada, and research collaborations spanning multiple continents. The company works closely with patient advocacy groups and academic centers to support clinical trials and foster patient access. Under the leadership of founder and Chief Executive Officer Emil Kakkis—an experienced clinician-scientist in the rare disease field—Ultragenyx continues to expand its capabilities in manufacturing, regulatory affairs and global commercialization to deliver transformative therapies for underserved patient populations.